ARGENX SE

efgartigimod

efgartigimod incorporates the ABDEG™ platform technology, for which we co-own the technology with the University

of Texas Southwestern Medical Center and enjoy certain exclusive license rights. We have a broad patent portfolio with

multiple patent families covering the composition of matter and uses of certain FcRn antagonists to achieve disease-

modifying effects. A composition of matter and other relevant patents arising from the same patent family in the U.S.

expire in 2036 and 2037 in Europe whereas in many other countries the base expiry date is 2034. We anticipate several

more patient innovations to evolve during development and commercialization for which we will seek additional patent

protection with later expiration dates.

Our ARGX-109 Product Candidate

With regard to our wholly-owned ARGX-109 product candidate, we have one patent family with composition of matter

claims directed to ARGX-109. The patent family has a base expiry date in 2033. We anticipate several more patient

innovations to evolve during development for which we will seek additional patent protection. Furthermore, ARGX-109

incorporates or employs the SIMPLE ANTIBODY™ platform technology and the NHANCE™ platform technology.

empasiprubart Product Candidate

With regard to the empasiprubart product candidate, we own or have rights to multiple patent families (with several

granted patents and pending patent applications in multiple jurisdictions in North America, South America, the EU and

Asia, directed to composition of matter claims and method of treatment claims. The patent families have base expiry

dates in 2034, 2039 and 2040. We anticipate several more patient innovations to evolve during development for which

we will seek additional patent protection. empasiprubart product candidate incorporates or employs the NHANCE™

platform technology.

adimanebart Product Candidate

With regard to the adimanebart product candidate, we in-licensed patent families from/with New York University

Langone Health, a U.S. medical center based in New York, and additional patent families from/with the Leiden

University Medical Centre, with a U.S. granted patent and several pending applications in multiple jurisdictions . We

anticipate several more patient innovations to evolve during development for which we will seek additional patent

protection.

Our ARGX-118 Product Candidate

With regard to the ARGX-118 product candidate, we co-own a patent portfolio with VIB, an inflammation research

center in Ghent, Brussels, and Ghent University, with one U.S. granted patent and pending patent applications in

multiple jurisdictions in North America, South America, the EU and Asia. The patent family has a base expiry date in